Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial

Jesper Frank Christensen; L W  Jones; Anders Tolver; L W  Jørgensen; J.L. Andersen; L  Adamsen; P. Højman; R. H.  Nielsen; Mikkel Rørth; Gedske Daugaard

doi:10.1038/bjc.2014.273

Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial

Jesper Frank Christensen, L W Jones, Anders Tolver, L W Jørgensen, J.L. Andersen, L Adamsen, P. Højman, R. H. Nielsen, Mikkel Rørth, Gedske Daugaard

16 Citationer (Scopus)

Abstract

Abstract Background: Bleomycin–etoposid–cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes. Methods: Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3–4 sets/exercise of 10–15 repetitions at 12–15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes. Results: Muscle fibre size decreased by −322 μm2 (95% confidence interval (CI): −899 to 255; P=0.473) in the CON-group and increased by +206 μm2 (95% CI: −384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 μm2, 95% CI: −253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 μm2, P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05). Conclusions: BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding.

Originalsprog	Engelsk
Tidsskrift	B J C
Vol/bind	111
Sider (fra-til)	8-16
ISSN	0007-0920
DOI	https://doi.org/10.1038/bjc.2014.273
Status	Udgivet - jul. 2014

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/bjc.2014.273

Citationsformater

@article{ca344ff014404a63985867a5884a18ec,

title = "Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial",

abstract = "Background:Bleomycin-etoposid-cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes.Methods:Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3-4 sets/exercise of 10-15 repetitions at 12-15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes.Results:Muscle fibre size decreased by-322 μm 2 (95% confidence interval (CI):-899 to 255; P=0.473) in the CON-group and increased by +206 μm 2 (95% CI:-384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 μm 2, 95% CI:-253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 μm 2, P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05).Conclusions:BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding.",

author = "Christensen, {Jesper Frank} and Jones, {L W} and Anders Tolver and J{\o}rgensen, {L W} and J.L. Andersen and L Adamsen and P. H{\o}jman and Nielsen, {R. H.} and Mikkel R{\o}rth and Gedske Daugaard",

year = "2014",

month = jul,

doi = "10.1038/bjc.2014.273",

language = "English",

volume = "111",

pages = "8--16",

journal = "B J C",

issn = "0007-0920",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy

T2 - a randomized controlled trial

AU - Christensen, Jesper Frank

AU - Jones, L W

AU - Tolver, Anders

AU - Jørgensen, L W

AU - Andersen, J.L.

AU - Adamsen, L

AU - Højman, P.

AU - Nielsen, R. H.

AU - Rørth, Mikkel

AU - Daugaard, Gedske

PY - 2014/7

Y1 - 2014/7

N2 - Background:Bleomycin-etoposid-cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes.Methods:Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3-4 sets/exercise of 10-15 repetitions at 12-15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes.Results:Muscle fibre size decreased by-322 μm 2 (95% confidence interval (CI):-899 to 255; P=0.473) in the CON-group and increased by +206 μm 2 (95% CI:-384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 μm 2, 95% CI:-253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 μm 2, P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05).Conclusions:BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding.

AB - Background:Bleomycin-etoposid-cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes.Methods:Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3-4 sets/exercise of 10-15 repetitions at 12-15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes.Results:Muscle fibre size decreased by-322 μm 2 (95% confidence interval (CI):-899 to 255; P=0.473) in the CON-group and increased by +206 μm 2 (95% CI:-384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 μm 2, 95% CI:-253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 μm 2, P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05).Conclusions:BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding.

U2 - 10.1038/bjc.2014.273

DO - 10.1038/bjc.2014.273

M3 - Journal article

C2 - 24867693

SN - 0007-0920

VL - 111

SP - 8

EP - 16

JO - B J C

JF - B J C

ER -

Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater